Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
The DOI matches its Crossref record; 132 of the 135 references it cites were found in a registry or an index.
Abstract
The concurrence of visceral obesity, insulin resistance and dyslipidaemia comprises the concept of the metabolic syndrome. The metabolic syndrome is an escalating problem in developed and developing societies that tracks with the obesity epidemic. Dyslipidaemia in the metabolic syndrome is potently atherogenic and, hence, is a major risk factor for CVD (cardiovascular disease) in these subjects. It is globally characterized by hypertriglyceridaemia, near normal LDL (low-density lipoprotein)-cholesterol and low plasma HDL (high-density lipoprotein)-cholesterol. ApoC-III (apolipoprotein C-III), an important regulator of lipoprotein metabolism, is strongly associated with hypertriglyceridaemia and the progression of CVD. ApoC-III impairs the lipolysis of TRLs [triacylglycerol (triglyceride)-rich lipoproteins] by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. In the circulation, apoC-III is associated with TRLs and HDL, and freely exchanges among these lipoprotein particle systems. However, to fully understand the complex physiology and pathophysiology requires the application of tracer methodology and mathematical modelling. In addition, experimental evidence shows that apoC-III may also have a direct role in atherosclerosis. In the metabolic syndrome, increased apoC-III concentration, resulting from hepatic overproduction of VLDL (very-LDL) apoC-III, is strongly associated with delayed catabolism of triacylglycerols and TRLs. Several therapies pertinent to the metabolic syndrome, such as PPAR (peroxisome-proliferator-activated receptor) agonists and statins, can regulate apoC-III transport in the metabolic syndrome. Regulating apoC-III metabolism may be an important new therapeutic approach to managing dyslipidaemia and CVD risk in the metabolic syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High ApoC-III levels were shown to increase total triglyceride levels by an accumulation of VLDL and chylomicrons [166–169]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [168]
In the citing paper
“In hypertriglyceridemia, more VLDL particles, as measured by apoB, and larger and more triglyceride-and apoC-III-enriched lipoproteins are found (39,64,65).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [65]
In the citing paper
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [65]
In the citing paper
“Consequently, APOC-III is considered an independent risk factor for cardiovascular disease [30, 31].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [31]
In the citing paper
“In contrast, apo C-III is an inhibitor of LPL, but also of hepatic lipase. Plasma apo C-III concentrations correlate positively with plasma TG [19].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [19]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., & Offermanns, S. (2003) · Nature Medicine · doi:10.1038/nm824 · Cited by 791
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
Garcia-Calvo, M., Lisnock, J., Bull, H. G., Hawes, B. E., Burnett, D. A., Braun, M. P., Crona, J. H., Davis, H. R., Dean, D. C., Detmers, P. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500269102 · Cited by 670
Research works printed but not linked: 4
- Assmann, 1998, The emergence of triglycerides as a significant independent risk factor in coronary artery disease, Eur. Heart J., 19, M8
- Ginsberg, 1986, Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceriderich lipoproteins by lipoprotein lipase in vivo, J. Clin. Invest., 78, 1287, 10.1172/JCI112713 · DOI · Paper page
- Sundaram, 2007, New insights into the roles of apolipoprotein C-III in stimulating the production of hepatic VLDL, Arteriosclerosis Thrombosis Vascular Biology Annual Conference, P142
- Clavey, 1995, Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E, Arterioscler. Thromb. Vasc. Biol., 15, 963, 10.1161/01.ATV.15.7.963 · DOI · Paper page
Cited by
Items 101–200 of 282
Basu, A., Bebu, I., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Budoff, M. J., Alaupovic, P., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p090647 · Cited by 30
“catabolism of triacylglycerols (TGs) (11).”
Wang, M., Xiao, F. L., Mao, Y., Ying, L., Zhou, B., & Li, Y. (2019) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2019.1635528 · Cited by 30
“[54] reported that apoC3 decreased the plasma TG levels by downregulating the apoC3 expression.”
BackgroundAPOC3 induces endothelial dysfunction through TNF-α and JAM-1
Tao, Y., Xiong, Y.-S., Wang, H., Chu, S.-P., Zhong, R., Wang, J., Wang, G., Ren, X., & Yu, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0326-0 · Cited by 33
Chan, D. C., Nguyen, M. N., Watts, G. F., Ooi, E. M. M., & Barrett, P. H. R. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28422 · Cited by 31
Self-citationLiu, J., Li, Y., Wei, L., Yang, X., Xie, Z., Jiang, T., Wang, C., Zhang, X., Xu, D., Chen, Z., et al. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.07.025 · Cited by 29
“In the circulation, it is associated with both triacylglycerol-rich lipoproteins (TRLs) and highdensity lipoprotein (HDL) (Shachter, 2001).”
BackgroundSoh, J., Josekutty, J., & Hussain, M. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00017-8 · Cited by 30
Hu, S., Cui, G., Huang, J., Jiang, J.-G., & Wang, D. W. (2016) · Scientific Reports · doi:10.1038/srep32700 · Cited by 30
The Complex Metabolic Mechanisms Relating Obesity to Hypertriglyceridemia
Eckel, R. H. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.233049 · Cited by 31
Lightbourne, M., Startzell, M. S., Bruce, K. D., Brite, B., Muniyappa, R., Skarulis, M. C., Shamburek, R. D., Gharib, A. M., Ouwerkerk, R., Walter, M. F., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.011 · Cited by 27
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
Meyers, N. L., Larsson, M., Vorrsjö, E., Olivecrona, G., & SMALL, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071126 · Cited by 30
“The hypertriglyceridemic phenotype associated with apoC-III is due to intracellular and extracellular regulation of TG metabolism (1, 8, 23).”
BackgroundInfluentialOniciu, D. C., Hashiguchi, T., Shibazaki, Y., & Bisgaier, C. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194568 · Cited by 28
“It is well known that ApoE present on VLDL-remnants, when not masked by ApoC-III, enhances VLDL-remnant clearance [42, 43].”
BackgroundDrenos, F., Davey Smith, G., Ala-Korpela, M., Kettunen, J., Würtz, P., Soininen, P., Kangas, A. J., Dale, C., Lawlor, D. A., Gaunt, T. R., et al. (2016) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.115.001302 · Cited by 26
“Using LPL (rs12678919) as a proxy for LPL protein levels, we tested the extent to which APOC3 action on lipids is mediated through LPL inhibition.12,17 Our results suggest that the great majority of the APOC3 effects are in line with the assumed mode of action through LPL; the composition of very large and medium VLDL…”
BackgroundInfluentialApolipoprotein CIII is a new player in diabetes
Juntti‐Berggren, L., & Berggren, P. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000372 · Cited by 30
Filippatos, T. D., Rizos, E. C., Tsimihodimos, V., Gazi, I. F., Tselepis, A. D., & Elisaf, M. (2013) · Lipids · doi:10.1007/s11745-013-3787-1 · Cited by 30
Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile
Filippatos, T. D., Tsimihodimos, V., Derdemezis, C. S., Gazi, I. F., Saougos, V. G., Mikhailidis, D. P., Tselepis, A. D., & Elisaf, M. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.07.002 · Cited by 26
“ApoC-III is a powerful inhibitor of LPL activity [4].”
BackgroundHieronimus, B., Griffen, S. C., Keim, N. L., Bremer, A. A., Berglund, L., Nakajima, K., Havel, P. J., & Stanhope, K. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070913 · Cited by 28
“ApoCIII is associated with increased CVD risk through various mechanisms, and several studies suggest it to be a robust and reliable predictor of CVD risk [26,27].”
BackgroundOta, V., Chen, E., Ejchel, T. F., Furuya, T. K., Mazzotti, D. R., Cendoroglo, M. S., Ramos, L. R., Araújo, L. Q., Burbano, R. M. R., & Smith, M. D. A. C. (2011) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31822467cd · Cited by 28
“APOC3 is a surface component of TG-rich lipoproteins and is a noncompetitive inhibitor of lipoprotein lipase.(7) APOC3 has been associated with CVD(8) and with higher TG levels.”
BackgroundHsieh, J.-Y., Chang, C., Huang, M. T.-H., Chang, C., Chen, C.-Y., Shen, M.-Y., Liao, H.-Y., Wang, G., Chen, C., Chen, C., et al. (2013) · Analytical Chemistry · doi:10.1021/ac402516u · Cited by 27
Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families
Bochem, A. E., van Capelleveen, J. C., Dallinga‐Thie, G. M., Schimmel, A. W. M., Motazacker, M. M., Tietjen, I., Singaraja, R. R., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., et al. (2014) · Clinical Genetics · doi:10.1111/cge.12201 · Cited by 24
“ApoCIII resides on both HDL and apoB-containing particles and acts on TG metabolism by inhibiting LPLmediated lipolysis (29).”
BackgroundNakou, E. S., Filippatos, T. D., Agouridis, A. P., Kostara, C., Bairaktari, E. T., & Elisaf, M. S. (2010) · Lipids · doi:10.1007/s11745-010-3409-0 · Cited by 23
“Furthermore, there is evidence that apoC-III exerts a direct effect on vascular and inflammatory functions, such as induction of adhesion molecules in vascular endothelial cells and activation of nuclear factor-kB [ 15 ].”
BackgroundInfluentialOrigin and therapy for hypertriglyceridaemia in type 2 diabetes
Pang, J., Chan, D. C., & Watts, G. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.165 · Cited by 26
Self-citationRaposo, H. F., Paiva, A. A., Kato, L. S., & Oliveira, H. C. F. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0058-6 · Cited by 27
“In addition, growing evidence has linked apoCIII concentrations in plasma lipoproteins, including HDL, to coronary heart disease [19, 20, 26, 27].”
BackgroundDonadio, C., Kanaki, A., Sami, N., & Tognotti, D. (2017) · Blood Purification · doi:10.1159/000476053 · Cited by 20
Apolipoprotein CIII and diabetes. Is there a link?
Christopoulou, E. C., Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3118 · Cited by 22
Rowell, J. V., Thompson, A., Guyton, J. R., Lao, X. Q., McHutchison, J. G., McCarthy, J. J., & Patel, K. (2011) · Hepatology International · doi:10.1007/s12072-011-9291-x · Cited by 21
Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis
Li, Y., Li, C., & Gao, J. (2016) · Meta Gene · doi:10.1016/j.mgene.2016.04.004 · Cited by 20
“A few genetic studies suggest that the single nucleotide polymorphisms (SNPs) in the APOC3 gene may have implications for hypertriglyceridemia (Talmud and Humphries, 1997) and susceptibility to CHD (Ooi et al., 2008).”
BackgroundGene-based therapies in lipidology: current status and future challenges
Gaudet, D., & Brisson, D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000240 · Cited by 20
“ApoC-III is a 79 amino acid glycoprotein synthesized mainly in the liver and, to a lesser extent, in the gut and binds to apoB or apolipoprotein A (apoA) containing lipoproteins, including chylomicrons, VLDL, intermediate-density lipoprotein, and LDL as well as HDL particles [17].”
BackgroundApoprotein C-III: A review of its clinical implications
Jin, J., Guo, Y., & Li, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.016 · Cited by 23
Krishnan, S., Copeland, K. C., Bright, B. C., Gardner, A. W., Blackett, P. R., & Fields, D. A. (2010) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00395.x · Cited by 19
“Furthermore, it has been shown to be a predictor of coronary events, progression of CV disease, and CV mortality.(18,19) ApoB levels also were strongly linked to CV risk in patients with T1D in a 15-year follow-up study in Switzerland.”
BackgroundHsu, M.-C., Cs, C., Lee, K.-T., Sun, H.-Y., Tsai, Y.-S., Kuo, P.-H., Young, K. C., & Wu, C.-H. (2013) · Nutrition and Diabetes · doi:10.1038/nutd.2013.2 · Cited by 18
Impact of Multiple Cardiovascular Risk Factors on Carotid Intima-Media Thickness and Elasticity
Niu, L., Zhang, Y., Qian, M. D., Meng, L., Xiao, Y., Wang, Y., Liu, X., Zheng, R., & Zheng, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067809 · Cited by 20
“In particular, triglyceride-rich lipoprotein remnants associated with apolipoprotein C-III appeared to have a major impact on risk [32,33].”
BackgroundNovel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
“ApoC-III is a 79 amino acid glycoprotein, which inhibits LPL activity [62].”
BackgroundSoto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Diakoumakou, O., Hatzigeorgiou, G., Gontoras, N., Boutsikou, M., Kolovou, V., Mavrogeni, S. I., Giannakopoulou, V., & Kolovou, G. D. (2014) · Cholesterol · doi:10.1155/2014/109263 · Cited by 20
“The disease generally comes to light in adult patients and rarely during childhood, with acute pancreatitis [33].”
BackgroundAmyloid Triangles, Squares, and Loops of Apolipoprotein C-III
de Messieres, M., Huang, R. K., He, Y., & Lee, J. C. (2014) · Biochemistry · doi:10.1021/bi500502d · Cited by 18
Koch, M., Furtado, J. D., Jiang, Z. G., Gray, B. E., Cai, T., Sacks, F. M., Tjønneland, A. M., Overvad, K., & Jensen, M. K. (2017) · Journal of Lipid Research · doi:10.1194/jlr.p073288 · Cited by 18
“apoC-III functions as a key regulator of triglyceride metabolism (5, 6).”
BackgroundDevelopment of Antisense Drugs for Dyslipidemia
Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 19
Primary genetic disorders affecting high density lipoprotein (HDL)
Kosmas, C. E., Silverio, D., Sourlas, A., Garcia, F., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212546 · Cited by 17
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
Bai, W., Kou, C., Zhang, L., You, Y., Yu, W., Hua, W., Li, Y., Yu, Y., Zhao, T., & Wu, Y. (2019) · PeerJ · doi:10.7717/peerj.6175 · Cited by 17
“The major function of APOC3 in lipid metabolism is to inhibit lipoprotein lipase (LPL); thus, the concentrations of plasma APOC3 are positively associated with TG concentrations (Ooi et al., 2008).”
BackgroundKatzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01293-9 · Cited by 17
Ramanjaneya, M., Butler, A. E., Bashir, M., Bettahi, I., Moin, A. S. M., Ahmed, L., Elrayess, M. A., Hunt, S. C., Atkin, S. L., & Abou‐Samra, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001925 · Cited by 16
Yanai, H., Katsuyama, H., & Hakoshima, M. (2022) · Biomedicines · doi:10.3390/biomedicines10020401 · Cited by 17
“Apo CIII inhibits LPL activity [29], which leads to further increase of VLDL and decrease of HDL.”
BackgroundOoi, E. M. M., Janus, E. D., Grant, S. J., Sinclair, L. M. T., & R.Barrett, P. H. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m004705 · Cited by 16
Self-citationAlantolactone suppresses APOC3 expression and alters lipid homeostasis in L02 liver cells
Yang, M., Zhao, H., Ai, H., Zhu, H., Wang, S., Bao, Y., & Li, Y. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.021 · Cited by 16
“In addition, the level of APOC3 is an independent predictor of CVD risk (Sacks et al., 2000; Ooi et al., 2008).”
Ling, C.-W., Deng, K., Yang, Y., Lin, H.-R., Liu, C.-Y., Li, B.-Y., Hu, W., Liang, X., Zhao, H., Tang, X.-Y., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105209 · Cited by 15
“ApoC, synthesized in the gut, 35 plays a crucial role in lipid metabolism.”
Backgroundde Souza, M. D. M., Mendes, B. X., Defante, M. L. R., Morais, B. A. D. A. D. H., Martins, O. C., Prizão, V. M., & Romaniello, G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156187 · Cited by 16
Kimak, E., Hałabiś, M., & Baranowicz-Gąszczyk, I. (2010) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1000012 · Cited by 15
Kassai, A., Muniyappa, R., Levenson, A. E., Walter, M. F., Abel, B. S., Ring, M., Taylor, S. I., Biddinger, S. B., Skarulis, M. C., Görden, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3891 · Cited by 15
Maraninchi, M., Padilla, N., Béliard, S., Berthet, B., Nogueira, J. P., Dupont-Roussel, J., Mancini, J., Corroller, A. B., Dubois, N., Grangeot, R., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.012 · Cited by 16
Sex-specific expression of apolipoprotein levels following replenishment of vitamin D
Al‐Daghri, N. M., Wani, K., Sabico, S., Garbis, S. D., Chrousos, G. P., Amer, O. E., Ansari, M. G. A., Al‐Saleh, Y., Aljohani, N. J., Al-Attas, O. S., et al. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.12.005 · Cited by 15
“vitamin D supplementation seems conflicting based on the atherogenic properties of apoC3 reported earlier [35], however, these findings could be partially explained by the fact that apoC3 is freely exchangeable between triglyceride rich lipoprotein and HDL systems; and apoC3 containing HDL particles seems to prevent a…”
BackgroundElevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia
Guan, Y., Hou, X., Tian, P., Ren, L., Tang, Y., Song, A., Zhao, J., Gao, L., & Song, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.646185 · Cited by 14
López-Valverde, L., Vázquez-Mosquera, M. E., Colón, C., Bravo, S. B., Gouveia, S., Álvarez, J. V., Sánchez‐Martínez, R., Mendoza, M. L., Rodriguez, M. L., Villacorta, E., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.02.006 · Cited by 14
Yamazaki, A., Ohkawa, R., Yamagata, Y., Horiuchi, Y., Lai, S.-J., Kameda, T., Ichimura, N., Tohda, S., & Tozuka, M. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0288 · Cited by 21
“Hence, although the phenomenon is well established, the factors and detailed mechanisms regarding apoC transfers between VLDL and HDL remain unclear (Kei et al. 2012; Ooi et al. 2008).”
BackgroundThe Differential Effects of HDL Subpopulations on Lipoprotein Lipase (LPL)-Mediated VLDL Catabolism
Wieczorek, E., Ćwiklińska, A., Kuchta, A., Kortas‐Stempak, B., Gliwińska, A., & Jankowski, M. (2021) · Biomedicines · doi:10.3390/biomedicines9121839 · Cited by 15
“Apo CII is an activator of LPL [10], whereas apo CIII acts as an LPL inhibitor [11].”
BackgroundLIPIDS IN CHRONIC KIDNEY DISEASE
Lewis, D., Haynes, R., & Landray, M. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00173.x · Cited by 14
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
Novel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13
“However, due to a founder effect, certain geographical regions show a higher prevalence [1].”
Afanasieva, O. I., Владиславович, Е. М., & Pokrovsky, S. N. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-99-109 · Cited by 16
Wang, R., Wang, Y., Tao, Y., Hu, L., Qiu, Q., Pu, Q., Yang, J., Wang, S., Huang, Y. Y., Chen, X., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c00019 · Cited by 13
“66 It could be hypothesized that the increment in protein abundance of Apoa1, Apoa2, and Apoc3 in the pancreas after CER injections contributed to altered transport and regulation of lipid metabolism and even inflammation.”
Li, F.-H., Wang, Y., Liu, X., & Xu, Q. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.122 · Cited by 14
RetractedKumar, H., Choo, H., Iskender, A. U., Srikanth, K., Kim, H., Zhunushov, A. T., Jang, G. W., Lim, Y., Song, K., & Park, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-76234-8 · Cited by 13
Xu, Q.-Y., Li, H., Cao, H., Pan, Q., & Fan, J. (2020) · BioMed Research International · doi:10.1155/2020/8869674 · Cited by 13
Genetic determinants of myocardial dysfunction
Li, X., & Zhang, P. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104308 · Cited by 13
Triglyceride‐rich lipoprotein metabolism in women: roles of apoC‐ II and apoC‐ III
Ooi, E. M. M., Chan, D. C., Hodson, L., Adiels, M., Borén, J., Karpe, F., Fielding, B. A., Watts, G. F., & Barrett, P. H. R. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12657 · Cited by 13
Self-citationMaidman, S. D., Hegele, R. A., & Rosenson, R. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01258-8 · Cited by 14
“VLDL = very low-density lipoprotein; IDL = intermediate-density lipoprotein; LDL = low-density lipoprotein; Apo = apolipoprotein found only on TRLs, namely chylomicrons, VLDL and their remnants [9, 12, 13].”
Okubo, M., Hanada, H., Matsui, M., Hidaka, Y., Masuda, D., Sakata, Y., & Yamashita, S. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.23309 · Cited by 11
Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia
Crooke, R. M., & Graham, M. J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.59 · Cited by 11
Yamamoto, T., Obika, S., Nakatani, M., Yasuhara, H., Wada, F., Shibata, E., Shibata, M., & Harada‐Shiba, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.004 · Cited by 11
“Thus, the privation of apoC-III would lead to significant benefits, both indirectly and directly, in the reduction of cardiovascular disease risk (Ooi et al., 2008; Pollin et al., 2008).”
BackgroundJenkins, A. J., Yu, Y., Alaupovic, P., Basu, A., Klein, R. L., Lopes-Virella, M. F., Baker, N. L., Hunt, K. J., Lackland, D. T., Garvey, W. T., et al. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.002 · Cited by 12
LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Hewing, B., & Landmesser, U. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0610-z · Cited by 13
Sandholm, N., Hotakainen, R., Haukka, J. K., Sigfrids, F. J., Dahlström, E. H., Antikainen, A. A., Valo, E., Syreeni, A., Kilpeläinen, E., Kytölä, A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01135-6 · Cited by 10
“, chylomicrons, VLDL, and IDL) and LDL particle, apoCIII is dynamically redistributed between these and HDL particles in the circulation [81].”
BackgroundChen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01983-0 · Cited by 13
“APOC3 is a multilamellar apolipoprotein that affects TG catabolism [46].”
BackgroundLiver protein expression in young pigs in response to a high-fat diet and diet restriction1
Sejersen, H., Sørensen, M. T., Larsen, T., Bendixen, E., & Ingvartsen, K. L. (2012) · Journal of Animal Science · doi:10.2527/jas.2012-5303 · Cited by 11
Minarikova, Z., Gašpar, Ľ., Kružliak, P., Celecová, Z., & Oravec, S. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-158 · Cited by 10
“Hypertriglyceridemic states are associated with increased VLDL production and delayed VLDL clearance from circulation [53-55].”
BackgroundThe RNA revolution in medicine: from gene regulation to clinical therapeutics
Jeong, J., & Jeong-Yu, S. (2025) · Animal Cells and Systems · doi:10.1080/19768354.2025.2548253 · Cited by 12
“APOC3 protein is a key regulator of lipid metabolism, as it inhibits LDL activity and the hepatic uptake of triglyceride-rich lipoprotein, ultimately impairing lipolysis (Ooi et al. (2008)).”
Relationship of Apolipoproteins with Subclinical Cardiovascular Risk in Youth
Czeck, M. A., Northrop, E. F., Evanoff, N. G., Dengel, D. R., Rudser, K. D., Kelly, A. S., & Ryder, J. R. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.08.017 · Cited by 10
JCL roundtable: Apolipoproteins as causative elements in vascular disease
Brown, W. V., Sacks, F. M., & Sniderman, A. D. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.003 · Cited by 9
Hypertriglyceridemia and Cardiovascular Outcomes
Malhotra, G., Sethi, A., & Arora, R. R. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000116 · Cited by 10
“Other evidence suggests that small dense LDL particles may be more susceptible to oxidative modification, and these factors adversely affect the cardiovascular risk.(15,16) Another important aspect is the presence of triglyceride-rich lipoproteins (TRLs), which play Hypertriglyceridemia and Cardiovascular Outcomes e863”
BackgroundClinical, biochemical and molecular analysis of two infants with familial chylomicronemia syndrome
Zhang, Y., Zhou, J., Zheng, W., Lan, Z., Huang, Z., Yang, Q., Liu, C., Gao, R., & Zhang, Y. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0254-z · Cited by 10
“in the liver and associated with apoB-containing lipoproteins and HDL, which has been reported to be a potent inhibitor of the activation of LPL [8].”
BackgroundApolipoproteins C-II and C-III as nutritional markers unaffected by inflammation
Isshiki, M., Hirayama, S., Ueno, T., Ito, M., Furuta, A., Yano, K., Yamatani, K., Sugihara, M., Idei, M., & Miida, T. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.03.004 · Cited by 10
“ApoC-III is found on chylomicrons, and plasma ApoC-III concentrations are elevated during both hyperlipidemia and diabetes [47, 48].”
BackgroundKurihara, O., Okajima, F., Takano, M., Kato, K., Munakata, R., Murakami, D., Miyauchi, Y., Emoto, N., Sugihara, H., Seino, Y., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311245 · Cited by 10
Álvarez-Jiménez, L., Morales‐Palomo, F., Moreno‐Cabañas, A., ORTEGA, J. F., & Mora‐Rodríguez, R. (2022) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.14193 · Cited by 10
Lipoprotein Metabolism and the Treatment of Lipid Disorders
Freeman, M. W., & Walford, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00041-x · Cited by 13
Basu, A., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Schade, D. S., Wood, J., Alaupovic, P., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p080143 · Cited by 8
“tions of Apo-C-III have been associated with CVD risk (13).”
BackgroundOlivieri, O., Cappellari, M., Turcato, G., Bonetti, B., Girelli, D., Pizzolo, F., Friso, S., Bassi, A., Castagna, A., & Martinelli, N. (2019) · Stroke · doi:10.1161/strokeaha.119.026811 · Cited by 10
“Apo CIII (apolipoprotein CIII) is a crucial regulator of plasma lipids, especially TRLs (triglyceride-rich lipoproteins), and is recognized as a causal risk factor for ischemic heart disease.(2) Increased Apo CIII plasma concentration is indeed a well-known predisposing condition for the development of atherosclerotic…”
BackgroundAkram, M. A., Khodja, A., Dalibalta, S., & Majdalawieh, A. F. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673348217241119063941 · Cited by 11
Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review
Luca, C. D., Ciciola, P., D’Errico, G., Taranto, M. D. D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Minno, M. N. D. D., & Calcaterra, I. L. (2025) · Genes · doi:10.3390/genes16111377 · Cited by 9
“Although available lipid-lowering therapies (fibrates, statins, and omega-3 fatty acids) decrease triglyceride levels [10,11], a not-negligible number of SHTG subjects do not achieve therapeutic goals [12].”
Bazarbashi, N., & Miller, M. J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.006 · Cited by 10
Dave, A., Park, E., Piya, S., & Pezzuto, J. M. (2025) · Foods · doi:10.3390/foods14040695 · Cited by 7
“Apoc3 can inhibit lipoprotein lipase thereby leading to increased triglyceride levels [56], but its role in muscle is not considered significant relative to its function in the liver, for example.”
Çoban, N., Onat, A., Güçlü-Geyik, F., Kömürcü-Bayrak, E., Sansoy, V., Hergenç, G., Can, G., & Erginel‐Ünaltuna, N. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.747 · Cited by 8
“Serum apoC-III, synthesized by the liver, is a constituent of chylomicrons, very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) (3) and plays a central role in TG metabolism (4, 5) .”
BackgroundWatts, L. M., Karwatowska‐Prokopczuk, E., Hurh, E., Alexander, V. J., Balogh, K., O'Dea, L. S. L., Geary, R. S., & Tsimikas, S. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0837 · Cited by 9
“APOC-III is a major regulator of lipoprotein metabolism and plays a pivotal role in regulating plasma triglyceride levels [4,5].”
Muralidharan, J., Papandreou, C., Soria-Florido, M. T., Sala‐Vila, A., Blanchart, G., Estruch, R., Martínez‐González, M. Á., Corella, D., Ros, E., Ruiz‐Canela, M., et al. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab362 · Cited by 7
Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment
Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 8
Postprandial triglyceride-rich lipoproteins in insulin resistance and Type 2 diabetes
Matikainen, N., & Taskinen, M. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.531 · Cited by 8
“ApoCIII inhibits LPL activity, impairs TRL hepatic clearance and seems to be associated with cardiovascular risk [46].”
BackgroundLu, X., Wang, Q., Liang, H., Xu, L., Sha, L., Wu, Y., Ma, L., Yang, P., & Lei, H. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s314935 · Cited by 7
“Plasma apo C-III concentrations correlate positively with plasma TG.(48) Apoprotein B100 is necessary for the secretion of VLDL, IDL, and LDL.”
BackgroundTryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III
Pfefferkorn, C. M., Walker, R. L., He, Y., Gruschus, J. M., & Lee, J. C. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.08.018 · Cited by 6
“Importantly, ApoCIII is an exchangeable apolipoprotein that moves from one lipoprotein to another [6, 7].”
BackgroundShieh, Y.-T., Chang, C., Toh, J.-J., Hsu, Y., Chang, I.-T., Hsia, M.-H., & Liu, M. (2020) · Electrophoresis · doi:10.1002/elps.202000065 · Cited by 6
Sydhom, P., Al-Quraishi, B., Gohar, A., El-Shawaf, M., Shehata, N., Ataya, M., Sydhom, M., Awwad, N., Motawade, H., Naji, N., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07798-8 · Cited by 5
“Consequently, APOC-III is considered an independent risk factor for cardiovascular disease [30, 31].”
Metadata
- Authors
- Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F.
- Affiliations
- The University of Western Australia (AU)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2008-04-14
- Volume
- 114
- Issue
- 10
- Pages
- 611-624
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2037283919
- Cited by
- 282
- References
- 135
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 12 · 2023: 11 · 2022: 12 · 2021: 16 · 2020: 18 · 2019: 22 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 10
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- National Institute of Biomedical Imaging and Bioengineering (P41EB001975)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, metabolic syndrome, hypertriglyceridemia, dyslipidemia, cardiovascular risk, triglyceride-rich lipoproteins, lipoprotein lipase inhibition, atherosclerosis, PPAR agonists, statins, lipoprotein metabolism
- MeSH terms
- Animals, Humans, Insulin Resistance, Intestinal Mucosa, Liver, Risk Factors, Triglycerides, Hypertriglyceridemia, Metabolic Syndrome, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.